Compare Moderna, Inc. (MRNA) vs Slide Insurance Holdings Inc. Common Stock (SLDE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Slide Insurance Holdings Inc. Common Stock — how do they compare? Moderna, Inc. trades at $223.31 (market cap $86.33B), while Slide Insurance Holdings Inc. Common Stock trades at $25.84 (market cap $3.00B). The key difference: Moderna, Inc. is far larger — about 28.8× Slide Insurance Holdings Inc. Common Stock's market cap, and Slide Insurance Holdings Inc. Common Stock pays a 1.09% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Slide Insurance Holdings Inc. Common Stock for 0 Days on average.
| MRNA | SLDE | |
|---|---|---|
Market Cap | $86.33B | $3.00B |
Volume | 13,361,426 | 1,061,663 |
Sector | Health | Financials |
52-Week High | $226.30 | $26.48 |
52-Week Low | $22.36 | $14.38 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $1.80B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
SLDE trades at $25.50, down slightly (-0.12%) on the day, with strong fundamental metrics including a P/E of 6.16 and net income margin of 40.02%. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results scheduled for October 27, 2026. Revenue growth from $1.16B in 2025 to projected $1.4B in 2026 demonstrates solid business momentum, supported by expanded insurance offerings in key markets.
The stock presents attractive value with strong profitability and analyst support (80% buy ratings), though hurricane exposure in Florida remains a key risk. Current price sits near consensus target of $25.00, suggesting limited near-term upside but solid fundamentals for long-term investors. Management's share repurchase program and dividend initiation provide additional shareholder value support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Slide Insurance Holdings Inc. Common Stock
Slide Insurance Holdings, Inc. is a technology-enabled insurance company based in Florida that underwrites coastal specialty personal lines insurance, including homeowners and condominium unit owner policies, and also provides reinsurance and insurance agency services.
Read more on SLDE →
